Metabolic Diseases and Exercise Effects on Platelets: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Sirius Huang and Version 1 by Isabella Russo.

Chronic disorders are strongly linked to cardiovascular (CV) diseases, and it is unanimously accepted that regular exercise training is a key tool to improving CV risk factors, including diabetes, dyslipidemia, and obesity. Increased oxidative stress due to an imbalance between reactive oxygen species production and their scavenging by endogenous antioxidant capacity is the common ground among these metabolic disorders, and each of them affects platelet function. Habitual physical exercise triggers important mechanisms related to the exercise benefits for health improvement and protects against CV events. Platelets play an important role in many physiological and pathophysiological processes, including the development of arterial thrombosis, and physical (in)activity has been shown to interfere with platelet function. Although data reported by studies carried out on this topic show discrepancies, knowledge on platelet function affected by exercise mainly depends on the type of applied exercise intensity and whether acute or habitual, strenuous or moderate, thus suggesting that physical activity and exercise intensity may interfere with platelet function differently. 

  • platelets
  • exercise
  • obesity
  • dyslipidemia
  • diabetes

1. Introduction

Cardiovascular (CV) diseases remain the leading cause of death globally. Physical exercise has been recognized as an important tool to prevent and treat disorders classically associated with increased risk of CV events [1,2][1][2]. Actually, regular physical training reduces CV death and rehospitalization in patients affected by coronary artery diseases (CAD) [3,4][3][4]. The mechanisms explaining the positive effects of regular physical training are only partially clarified. However, a large body of evidence unanimously indicates regular exercise training as a key tool to improve CV risk factors, including diabetes, dyslipidemia, and obesity [3,5,6][3][5][6]. Notably, each of these metabolic disorders affects platelet function [7], and the correction of hyperglycemia in subjects with diabetes [8] and lipid profile in subjects with dyslipidemia [9[9][10],10], as well as lowering the body weight in subjects with obesity [11] all correlate with amelioration of platelet function. Increased oxidative stress due to an imbalance between reactive oxygen species (ROS) production and their scavenging by endogenous antioxidant capacity is the common ground among these metabolic disorders [12]. In particular, when subcellular concentrations of ROS increase beyond homeostatic levels in endothelial cells, the vascular effects of nitric oxide (NO) are compromised, resulting in endothelial dysfunction [13]. Thus, the improvement of platelet function in these dysmetabolic conditions would require a shift in the ROS/NO balance to favor NO within the vasculature.
Metabolic dysfunctions are often characterized by the co-existence of endothelial dysfunction, pro-inflammatory cytokine release, and hypercoagulable state, due at least in part to impaired hemostasis, with a strong interplay with each other.
Platelets exert a crucial role in hemostasis and are well-recognized as key players in the development of arterial thrombosis. This role is also closely dependent on platelet ability to release several growth factors and inflammatory molecules involved in the development of CV diseases, which, in turn, are often associated with platelet hyperreactivity. Also, physical (in)activity has been shown to interfere with platelet function. Although data reported by studies carried out on this topic show discrepancies, the current knowledge on platelet function affected by exercise mainly depends on the type of applied exercise intensity and whether acute or habitual, strenuous, or moderate, thus suggesting that physical activity and exercise intensity may interfere with platelet function differently. This is in line with the well-known relationships between physical activity and risk for CV events, where strenuous exercise can increase the risk for myocardial infarction, whereas regular and moderate physical activity significantly decreases the risk of fatal CV events [14,15][14][15]. This is an important aspect because the effects of platelet activation are increasingly recognized to be crucial not only for the final step of CV outcomes but also for their involvement in the development and progression of CV dysfunction. Therefore, it is not surprising that there is a mechanistic correlation between the effects of physical activity on platelet function and CV disease-related mortality. Taking into account the important role of exercise in redox status and oxidative stress in the pathways involved in platelet activation, it is reasonable to suppose an association between the protection against CV disease from physical exercise and the effects of exercise on platelet function (Figure 1).
Figure 1. Effects of different types of physical activity on the increased risk of thrombus formation and cardiovascular (CV) events. Sedentary habits induce vascular inflammation that can lead to metabolic diseases. In the same way, prolonged intense training can promote an inflammatory milieu in blood vessels. Reactive oxygen species (ROS) production increases during both types of exercise, reducing nitric oxide (NO) availability and leading to platelet activation, which can contribute to CV events in the long term. Moderate and constant physical activity over time increases the bioavailability of NO, a potent platelet inhibitor, lowering the CV risk. Abbreviations: cyclooxygenase (COX); nicotinamide adenine dinucleotide phosphate (NADPH).

2. Metabolic Diseases and Exercise Effects on Platelets

Metabolic disorders, including obesity, dyslipidemia, and diabetes are well established risk factors for CVDs [145][16], being associated with underlying abnormalities that trigger some common biochemical events influencing platelet response, such as enhanced ROS formation, decreased availability and/or synthesis of NO, lipid peroxidation with the consequent increased production of TXA2 and free radicals, and non-enzymatic–catalyzed generation of bioactive isoprostanes, which activate TX receptor [11,146,147][11][17][18].
In each of these metabolic disorders, it is reasonable to suppose that physical activity, with or without weight reduction, reduces cardiometabolic disorder risk, partially by improving insulin sensitivity and lowering blood pressure [148,149][19][20]. Indeed, among the biological mechanisms by which exercise confers its benefits, the increased sensitivity to both the metabolic [150,151][21][22] and vascular [152][23] actions of insulin may play an important role. Platelet membrane expresses insulin receptors with a density similar to that of cell types of the targets of the metabolic actions of the hormone [153][24]. Platelet insulin receptors activate the intracellular pathway classically linked to insulin signaling, even in the absence of a response of glucose uptake [154][25]. Obese insulin-resistant subjects with or without diabetes show impaired platelet responsiveness to the inhibitory effects of insulin [25[26][27],155], thus suggesting that each strategy useful in reducing insulin-resistance can also improve the vascular effects of insulin including its antiplatelet effects.
Platelet Alterations in Obesity. One of the first epidemiological studies showing a strong correlation between obesity and CV events was the Framingham Heart Study [156,157][28][29]. From then, many other studies have confirmed the role of waist-to-hip ratio (WHR), an index of central obesity, as the strongest anthropometric predictor of myocardial infarction [158][30] and stroke [159,160][31][32].
The release of cytokines and free fatty acids from abdominal adiposity has a causal, unfavorable effect on lipid profile and other cardiometabolic risk factors involved in the pathogenesis of both atherothrombosis and insulin resistance [161,162][33][34]. Chronic low-grade inflammation and systemic oxidative stress have both been associated with obesity causing endothelial dysfunction with the consequent loss of its antithrombotic properties and arterial damage, thus justifying the assumption that obesity is a pro-thrombotic condition due to vascular disease, increased platelet activation, and hypercoagulability [163,164,165,166,167][35][36][37][38][39]. Adipose tissue is an important source of ROS and the increased level of systemic oxidative stress contributes to the development of obesity-associated insulin resistance and type 2 diabetes mellitus (T2DM) and other disorders, such as hypertension, atherosclerosis, and cancer [168,169][40][41]. Excess intake of nutrients, a sedentary lifestyle, and the consequent weight gain promote ROS production and mitochondrial dysfunction [170][42], a risk factor for T2DM, atherosclerosis, and hypertension [171][43]. Among the in vivo parameters of platelet activation, MPV, a marker closely related to platelet hyperactivation, has been found to be increased in obesity [17[44][45][46],172,173], and a positive correlation also exists between MPV and body mass index (BMI) after weight loss [172,174,175][45][47][48]. A platelet activation marker associated with obesity is also sP-sel, which is able to predict atherosclerosis independently of BMI and other CVD risk factors [176][49]. The increased circulating levels of sP-sel found in overweight and obese subjects [11,177][11][50] are reduced after weight loss [11]. Obese subjects show increased levels of 11-dehydro-TXB2 and PGF2α, thus underlining the link between platelet activation and oxidative stress [178][51]. Indeed, the chronic ‘metabolic inflammation,’ which is considered the hallmark of obesity and causes insulin resistance and T2DM [179][52], significantly contributes to increases in the systemic levels of ROS, which affect platelet reactivity by different mechanisms, including decreased NO bioavailability, increased expression of membrane glycoproteins, impairment of calcium mobilization, and isoprostane generation [178][51]. In obesity, in comparison with non-obese subjects, elevated PMP levels positively correlate with BMI and waist circumference [180][53], although this finding was not confirmed in other studies, where PMP did not appear to differ in number [181][54] but were greatly heterogeneous in size and distribution, with different levels of proteins involved in thrombosis and tumorigenesis [181][54].
In previous studies, the researchers provided evidence of persistent platelet hyporesponsiveness to NO and PGI2 pathways in obesity and T2DM [26,182,183][55][56][57]. Researchers demonstrated the presence of multi-step defects at the level of NO/cGMP/PKG and PGI2/cAMP/PKA pathways. Specifically, platelets from obese subjects show an impairment in the respective abilities of NO and PGI2 to increase cGMP and cAMP synthesis, and resistance of cGMP and cAMP themselves in activating their specific kinases PKG and PKA [26,182][55][56]. As these are cyclic nucleotides effective in reducing intracellular Ca2+ [184][58], the data explained one of the mechanisms implicated in Ca2+ flux alterations found in insulin-resistance states [185][59] and the defective action of cyclic nucleotides on platelet function. In addition, hyperglycemia does not emphasize this multistep resistance [186][60], and the presence of diabetes without obesity is not associated with platelet abnormalities observed in obese subjects [186][60]. These findings support the hypothesis that the abnormalities leading to platelet hyperreactivity are mainly related to the underlying metabolic disorders dependent on visceral adipose tissue activity rather than on platelet exposure to hyperglycemia effects. Besides changing subcutaneous and visceral adipose tissue distribution, insulin sensitivity, and beta-cell performance, a dietary program aiming at achieving weight loss of at least 7–10% of initial body weight leads to a significant reduction in systemic inflammation, oxidative stress, lipid peroxidation, and platelet reactivity [11].
Exercise Effects on Platelets in Obesity. A recent systematic review and meta-analysis including 25 randomized controlled trials (1686 participants) shows that regular aerobic exercise significantly decreases visceral adipose tissue with more pronounced benefits for higher intensity exercise [187][61]. It has also been ascertained that independently of age, body mass index, and exercise training characteristics, aerobic training in adults with overweightness or obesity and with cardiometabolic disorders is effective in reducing postprandial glucose and insulin levels [188][62]. As far as platelet parameters are concerned, a randomized clinical trial performed in overweight men showed that moderate-intensity training for 12 weeks consisting in walking/slow jogging exercise at 45–55% of VO2 max (5x/week for 45–60 min) led to a reduction in platelet aggregation associated with a reduction in serum TXB2 levels [135][63]. To determine the role of exercise in platelet reactivity in obese patients with coronary artery disease, a 4-month program of training exercise and behavioral weight loss was performed by Keating et al. [189][64]. These authors found a significant decrease in P-sel expression not independently associated with measures of body composition or fitness. After controlling for exercise group and gender, the change in platelet reactivity was more pronounced in females and associated with changes in high-sensitivity C-reactive protein and a reduction in insulin-resistance. A study carried out on blood samples taken from obese women before and immediately after exercise demonstrated that vigorous aerobic exercise, consisting of a 30-min walking exercise test at an intensity of 70% of individual peak oxygen uptake, was able to significantly prolong the clot formation time as measured by thromboelastometry and reduce the fibrin buildup after exercise. Thrombography revealed a significant exercise-induced decrease in endogenous thrombin potential [121][65]. On the basis of these results, the authors postulated that vigorous aerobic exercise might be a suitable strategy to protect obese women from thrombotic events. Indeed, this assertion has been confuted in favor of regular exposure to high-intensity exercise in order to desensitize against exercise-induced platelet aggregation, attenuate coagulatory parameters, and up-regulate fibrinolytic potential [87][66]. In another study, obese subjects underwent moderate-intensity exercise on a treadmill (at 60% of their VO2 max), and the results showed changes in size distribution and cell origin of extracellular vesicles (EVs) [190][67]. Total EVs, exosomes, and CD61+ EVs were significantly associated with HOMA-IR, and flow cytometry assays revealed that acute exercise provided a significant improvement of hemostasis parameters, including reduced platelet aggregability [191][68] (Table 1).
Platelet Alterations in Dyslipidemia. Dyslipidemia promotes the atherosclerosis process because of the chronic accumulation of lipid-rich plaque in arteries [192][69], and its relationship with the increase in CV risk depends on its long-term effects on atherogenesis as well as on its influence on thrombogenesis [28][70]. Lipid profile alterations are associated with increased oxidative stress, and the generation of oxidized lipids, such as ox-LDL, leading to platelet hyperreactivity [16,193][71][72]. In turn, activated platelets can generate ox-LDL, thus contributing to propagating platelet activation, and inducing thrombus formation through oxidative stress-mediated mechanisms. In particular, the ROS-producing enzyme nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase (NOX)-2 (NOX2)-dependent increase in oxidative stress is involved in platelet ability to propagate the oxidation of lipoproteins [194,195][73][74]. Oxidized lipoproteins are deeply involved in many biochemical events leading to atherosclerosis processes as well as platelet hyperactivation [196,197][75][76].
Platelet hyperreactivity, strongly and independently associated with thrombotic events [198[77][78][79][80][81],199,200,201,202], is characterized by redox imbalance [9,10,203][9][10][82]. Mechanistically, ROS and oxidation reactions are, per se, the cause of vascular dysfunction [168[40][83][84],204,205], but dyslipidemia also increases the risk of CVDs due to the effects of plasma oxidized lipids on platelet function [206][85] via the interaction of ox-LDL with scavenger receptors, such as CD36, and signaling pathways, including the Src family kinases (SFK), mitogen-activated protein kinases (MAPK), and NADPH-oxidase.
In their native form, LDL particles do not increase platelet aggregation, whereas their oxidative modifications make these lipoproteins able to act as aggregating agents in the absence of physiological agonists [207][86]. In hypercholesterolemia, the loss and/or impaired effects of NO on platelets are important determinants for platelet hyperactivation. The increased oxidative stress causes a decrease in NO bioavailability [208][87] and a decreased sensitivity to NO-related pathways [11,209,210,211][11][88][89][90]. Additionally, a lower NO-mediated inhibitory effect of the incretin hormone glucagon-like peptide 1(GLP-1) [212][91] has been found as a putative mechanism by which hypercholesterolemia can induce platelet hyperactivation [209][88]. Patients with hypercholesterolemia show increased levels of TXA2, superoxide anion, and platelet activation markers, including sP-Sel, PF-4, sCD-40L, and β-TG [9,10,203][9][10][82]. Importantly, the reductions in oxidative stress-related abnormalities obtained through pharmacological interventions can significantly improve platelet function. Indeed, many platelet alterations significantly improve after treatment with classical lipid-lowering drugs, such as statins [10,81,213,214[10][92][93][94][95][96],215,216], and the more recent and aggressive therapies, such as the anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies [9,217][9][97].
Exercise, Lipid Metabolism, and Platelets. Exercise has positive impacts on reducing cholesterol levels and improving the physical fitness of individuals with dyslipidaemia [218][98]. A significant positive association exists between exercise and HDL cholesterol, while a significant negative association has been reported between exercise and triglyceride levels, total cholesterol, LDL cholesterol, and triglycerides after a 5-year follow-up [219][99]. It is generally accepted that regular physical exercise, with a linear dose–response relationship, increases HDL cholesterol while regulating and theoretically preventing increases in LDL cholesterol and triglycerides [220][100]. More intense activity seems required to obtain significant reductions in LDL cholesterol and triglyceride levels, even if a bout of prolonged aerobic exercise has been shown to be effective in lowering blood postprandial hypertriglyceride levels in individuals at high risk of developing CVD [221][101]. Indeed, exercise modality, cardiovascular exercise type, and timing of exercise can vary in their attenuation of postprandial triglyceride levels depending on exercise energy expenditure prior to meal administration [222][102].
As known, exercise increases oxygen consumption with the consequent increase in oxygen-related free radicals. The increased exercise-mediated oxidative stress can induce lipid peroxidation, membrane damage, and platelet activation due to the effects of both native LDL and LDL modified under oxidative stress on platelets [223,224][103][104]. The deleterious effect of strenuous exercise on platelet activity has been confirmed by a study carried out on healthy subjects showing an increase in plasma TX level at peak exercise and its return to pre-exercise levels at 10 min postexercise [84][105]. Intriguingly, this study also showed that a treadmill exercise test to the point of physical exhaustion induced platelet aggregation, increased TX, β-TG, and lipid peroxide levels. However, that acute exercise decreased LDL lipid peroxides, reaching a statistically significant lower plasma concentration at 10 min post-exercise. The authors speculated that during strenuous exercise, LDL lipid peroxides can replace plasma LDL cholesterol (LDL-C), attenuating the role of LDL on platelet activation. To explain this paradoxical result, ex vivo experiments were also performed by adding mildly oxidized LDL to peak exercise blood. The result was a decrease in platelet aggregation, suggesting that LDL lipid peroxides attenuate exercise-induced platelet aggregation. However, the question of why mildly ox-LDL, in conditions of strenuous exercise, attenuated instead of stimulating platelet aggregation remains to be explored.
In another study, sedentary individuals performing exercise training for 8 weeks failed to decrease their circulating ox-LDL levels but reduced plasma total cholesterol and LDL-C levels and positively influenced platelet function, as demonstrated by the reduced ability of ox-LDL added in vitro to increase the agonist-induced aggregation and intraplatelet calcium elevation in blood samples collected at both resting and postexercise [75][106]. However, detraining reverses the benefits of training on lipid profile and platelet function, and in contrast to regular, strenuous acute exercise, it increases platelet aggregation and calcium elevation promoted by 100 microg/mL of ox-LDL [75][106]. These findings confirm the positive effects of the adaptation to long-term exercise training.
Besides lipid profile amelioration, the high-fat diet combined with the swimming group is able to improve many hemostasis parameters, including platelet reactivity, as shown by prolonged bleeding time, reduced platelet aggregability and spread of fibrinogen, and decreased activation of pathways implicated in platelet activation [225][107].
The effects of an 8-week high-intensity aerobic exercise on in vivo lipid peroxidation and platelet activation were investigated in healthy sedentary individuals with low HDL cholesterol levels. Exercise training did not modify total cholesterol or LDL-C concentrations but significantly reduced oxidative stress (8-iso-PGF2α) and platelet activation (11-dehydro-TXB2) urinary markers [226][108] (Table 1).
Platelet Alterations in Diabetes. Several studies provide evidence of the enhanced activation of platelets in T2DM [227,228,229,230,231][109][110][111][112][113]. Increased values of MPV, an indicator of platelets larger in size and metabolically more active, and platelet distribution width (PDW) are indicative of platelet activation and associated with thrombotic events [232][114]. The consequent platelet hyperreactivity triggers the release of multiple molecules stored in α-granules, dense granules, and lysosomal granules.
The persistent platelet activation represents an important link between diabetes and atherothrombosis, although evidence from the literature shows platelet activation already in prediabetes [233][115] or newly diagnosed T2DM patients with central obesity in good metabolic control [234][116]. Indeed, lipid peroxidation and TX-dependent platelet activation, as mirrored by in vivo urinary excretion of PGF2α and 11-dehydro-TXB₂, correlate with atherothrombosis from the earlier stages of T2DM [234][116]. Nevertheless, a linear correlation was observed between the urinary excretion of the stable TX metabolite 11-dehydro-TXB2 and either body mass and plasma fasting or postprandial glucose. The exact role of adiposity, adipose tissue inflammation, insulin resistance, and hyperglycemia in persistent platelet hyperreactivity in diabetes is difficult to clarify. Hyperglycemia is not a strong risk factor for CVD [235[117][118],236], as confirmed by the evidence that interventions aimed at reducing plasma glucose did not significantly reduce CV risk and mortality [237,238,239][119][120][121]. Consistently, the pharmacological reduction in glycated hemoglobin (HbA1c) only modestly improved CVD risk and mortality [235[117][121],239], whereas newer drugs, including GLP-1 agonists and gliflozins, beyond their glucose-lowering effects, have provided effective results in terms of reduction in CV risk [240[122][123][124],241,242], thus indicating the need to modulate risk factors other than hyperglycemia to blunt atherothrombosis [243][125].
Exercise Effects on Platelets in Diabetes. Besides cardio-pulmonary fitness and weight control, exercise training improves glycemic control and insulin-resistance in T2DM [244][126] and is strongly recommended for its benefits on the CV system [245][127]. A total of 106 randomized controlled trials involving 7438 patients were included in a recent meta-analysis aimed at evaluating exercise effects in adults with T2DM. In comparison with no exercise, low to moderate supervised aerobic/resistance exercise is associated with significant improvement of glycemic and lipid profile, body weight, and blood pressure [187][61].
Regular physical exercise in diabetes also shows beneficial effects on platelet function (Table 1). Specifically, aerobic training for 8 weeks determines a remarkable reduction in MPV, PDW, and collagen-induced platelet aggregation [246][128], attributable at least in part to downregulated glycoprotein (GP)IIb expression. A 12-week moderate-intensity aerobic exercise program was effective in upregulating platelets’ microRNAs (miRNA)-223 and downregulating P2RY12 receptor expression following decreased platelet aggregability in T2DM patients [247][129], whereas short-term endurance training determined a positive impact on platelet function, glycemic indices, physical fitness, and body composition, but did not change miRNA-223 levels and P2RY12 expression [248][130]. One year of exercise training was not effective in modifying platelet-derived microvesicles in T2DM patients with CAD, but decreased levels of PMVs carrying TF [CD61+/CD142+/Annexin V (AV)+] and von Willebrand factor (vWF; CD31+/CD42b+/AV+) in those with albuminuria [249][131]. In another study, acute exercise increased platelet aggregation in diabetic subjects despite treatment with aspirin diabetics, thus showing the limited effects of aspirin in inhibiting exercise-induced platelet aggregation [250][132]. The impaired action of aspirin could be partially explained by taking into account that endothelial dysfunction caused by inflammation and oxidative stress causes an impaired release of PGI2 and NO following acute exercise, thus limiting the antiplatelet effects of aspirin [251][133]. Another randomized crossover design evaluated the short-term effects of post-meal walking exercise with and without a low-carbohydrate diet on vascular parameters. The authors found that a 15-min post-meal walk in addition to a diet significantly improved endothelial function, even if its role in platelet reactivity, as measured through PMP release and monocyte platelet aggregate (MPA) count and percentage, was unclear [252][134]. The effects of postprandial hyperglycemia in impairing endothelial function and increasing oxidative stress are particularly concerning for their role in the excessive CVD risk in diabetes [253[135][136],254], and the correction of hyperglycemia and oxidative stress can positively influence endothelial function, at least in an acute setting [255][137]. A limitation of this study was certainly its short duration, which did not allow the observation of the endothelium-mediated benefits for platelets. In a study carried out by Scheinowitz et al., diabetic patients in antiaggregating therapy with aspirin were enrolled and undertook acute exercise. Platelet samples at rest and immediately post-exercise were stimulated with agonists, and the expression of the pan-platelet marker CD41 and platelet activation marker CD62P was measured [256][138]. Despite diabetic patients showing systolic blood pressure significantly higher than non-diabetics, no differences were found in platelet parameters. Finally, platelet CD markers of platelet activation did not change in a study comparing the effects of blood-flow restriction under low-intensity resistance exercise (20%) versus high-intensity resistance exercise (80%) in female T2DM patients, even though CD62P, CD61, CD41, and CD42 were reduced following resistance exercise in both trials independently of blood-flow restriction conditions [257][139] (Table 1).
Table 1. Exercise and platelet parameters in metabolic diseases. Abbreviations: adenosine diphosphate (ADP); adenosine triphosphate (ATP); thromboxane B2 (TXB2); platelet (PLT); coronary artery disease (CAD); cardiac rehab (CR); high caloric CR (HCR); extracellular vesicles (EVs); exercise (EX); high carbohydrate and fat diet (HCFD); high-fat (HF); high-fat + exercise (FE); oxidized Low-Density Lipoprotein (ox-LDL); prostacyclin (PGI2); coronary heart disease (CHD); high-density lipoprotein cholesterol (HDL-c); prostaglandin F2α (PGF2α); mean platelet volume (MPV); platelet distribution width (PDW); plateletcrit (PCT); type 2 diabetes mellitus (T2DM); monocyte-platelet aggregates (MPAs); blood-flow restriction (BFR).
Study Design Population Number of Individuals Exercise Protocol Platelet Parameters Effects of Exercise Reference
Obesity            
Randomized controlled trial Men 53 Progressive training program for 12 weeks ADP-induced platelet aggregation ↓ ADP-induced PLT aggregation (Ex group vs. Ref group) [135][63]
    Exercise group: 26 Sessions: five times/week, 45 to 60 min per session. Release of ATP No significant change  
    Reference group: 27   Serum TXB2 ↓ TXB2 (Ex group vs. Ref group)  
Prospective randomized trial CAD 46

Cases CR: 21 standard cardiac rehab (CR)

Cases HCR: 25 high caloric CR		 All: 4 months of intervention + 1 month of weight stabilization with training

CR: 3 sessions/week of 25 to 40 min

HCR: 5 to 7 sessions/week of 45 to 60 min		 P-Selectin expression

GPIIb/IIIa activation		 ↓ P-Selectin expression (5 months vs. baseline, all subjects)

↓ P-Selectin expression (5 months vs. baseline, HCR)

GPIIb-IIIa activation no significant change (5 months vs. baseline, all subjects)		 [189][64]
Controlled clinical intervention study Women 42 All: 30-min walking exercise test with an intensity of 70% of individual peak VO2 Thrombus formation

Collagen-induced platelet aggregation

Platelet adhesion		 ↑ clot formation time (post vs. pre)

↓ alpha-angle (post vs. pre)

No significant change		 [121][65]
        PLT count No significant change  
Case-control study   23 All: in two different days two exercise protocols PLT EVs (CD61+) ↓ PLT EVs (postexercise 24 h vs. basal, all subjects) [190][67]
    Cases: 15 Pilot test: incremental exercise on a treadmill until voluntary exhaustion      
    Controls: 8 Submaximal test: 30 min of moderate constant workload      
Randomized controlled trial Rats 24 All: 15 weeks ADP-induced platelet aggregation ↓ ADP-induced PLT aggregation (HCFD + Ex vs. HCFD) [191][68]
    Cases Ex: 6 Group Ex: swimming 3 days/week, 1 h PLT count No significant change  
    Cases HCFD: 6 Group HCFD: high-fat diet      
    Cases HCFD + Ex: 6 Group HCFD + Ex: high-fat diet + swimming from the 11th week to the 15th week      
    Controls: 6 Controls: no exercise training      
Lipid Profile

Alterations		            
Randomized controlled trial Mice 63 All: 8 weeks PLT aggregation rate ↓ PLT aggregation rate (FE vs. HF) [186][60]
    Controls: 21 Cases HF: high fat diet PLT spread on fibrinogen ↓ PLT spread on fibrinogen (FE vs. HF)  
    Cases HF: 21 Cases FE: swimming 60 min/day, 5 days/week PLT pAKT level ↓ PLT pAKT level (FE vs. HF)  
    Cases FE: 21        
Randomized controlled trial Sedentariety 10 1. Strenuous, acute exercise ADP-induced PLT aggregation ↑ ADP-induced PLT aggregation (strenous ex vs. rest) [75][106]
      2. Ergometer cycling: ADP-induced [Ca2+]i elevation ↑ ADP-induced [Ca2+]i elevation (strenous ex vs. rest)  
      30 min/day, 5 days/week, 8 weeks ox-LDL-induced PLT aggregation ↑ ox-LDL-induced PLT aggregation (strenous ex vs. rest)  
      3. 12 Weeks detraining ox-LDL-induced [Ca2+]i elevation ↑ ox-LDL-induced [Ca2+]i elevation (strenous ex vs. rest)  
          ↓ ADP-induced PLT aggregation (training vs. pre-training)  
          ↓ ADP-induced [Ca2+]i elevation (training vs. pre-training)  
          ↓ ox-LDL-induced PLT aggregation (training vs. pre-training)  
          ↓ ox-LDL-induced [Ca2+]i elevation (training vs. pre-training)  
          ↑ ADP-induced PLT aggregation (detraining vs. training)  
          ↑ ADP-induced [Ca2+]i elevation (detraining vs. training)  
          ↑ ox-LDL-induced PLT aggregation (detraining vs. training)  
          ↑ ox-LDL-induced [Ca2+]i elevation (detraining vs. training)  
Randomized controlled trial Healthy 30 Treadmill test using Bruce protocol Plasma TX levels ↑ plasma TX levels (pre vs. post) [84][105]
        Plasma PGI2 levels No significant change  
        After ex vivo addition of mildly ox-LDL:    
        TX release ↓ TX release (mildly ox-LDL+ vs. mildly ox-LDL-)  
        Collagen-induced PLT aggregability ↓ collagen-induced PLT aggregability  
          (mildly ox-LDL+ vs. mildly ox-LDL-)  
Cross-sectional study CHD 18 All: 8 weeks Urinary 8-iso-PGF2a ↓ Urinary 8-iso-PGF2a (post vs. pre) [219][99]
  Sedentariety   2 sessions/week on cycle ergometer Urinary 11-dehydro-TXB2 ↓ Urinary 11-dehydro-TXB2 (post vs. pre)  
  Low HDL-c   55 min/session, supervised      
DIABETES            
Randomized controlled trial   24 All: 12 weeks ADP-induced PLT aggregation ↓ ADP-induced PLT aggregation (Cases vs. Controls) [240][122]
    Cases: 12 Cases: walking and running on the treadmill in

Non-consecutive days		 miRNA-223 expression ↑ miRNA 223 expression (Cases vs. Controls)  
    Controls: 12 Controls: no exercise training      
Quasi-experimental controlled trial Sedentariety 24 All: 8 weeks Collagen-induced PLT aggregation ↓ collagen-induced PLT aggregation (post vs. pre, cases) [239][121]
      Cases: mean intensity treadmill, 3 times/week PLT, MPV, PDW, PCT ↓ MPV, ↓ PDW (post vs. pre, cases)  
      Controls: no exercise training Glycoprotein IIb (GPIIb) receptor expression Down-regulated (post vs. pre, cases)  
        miR-130a expression No significant change  
Randomized controlled trial CAD 74 All: 12 months PMVs No significant change [242][124]
  Albuminuria (n = 25) Cases: 38 Cases: aerobic and resistance training PMVs in patients with albuminuria ↓ PMVs carrying TF (CD61+/CD142+) (post vs. pre, cases)  
    Controls: 36 150 min/week   ↓ PMVs carrying vWF (CD31+/CD42b) (post vs. pre, cases)  
Prospective study Aspirin treatment 79 All: single treadmill exercise test PLT aggregation (ASPI test) Cases: ↑↑ PLT aggregation (post vs. pre) [243][125]
  Cases: T2DM Cases: 43     Controls: ↑ PLT aggregation (post vs. pre)  
  Controls: no T2DM Controls: 36        
Randomized crossover study   11 All: post-meal walks PMVs No significant change [245][127]
      15 min/day MPAs ↑ MPAs (post vs. pre, cases)  
      4 days      
Randomized controlled trial Cases: T2DM 16 1 session of nuclear exercise stress test PLT count No significant change [249][131]
  Controls: no T2DM Cases: 8 Bruce protocol ADP-induced PLT activation No significant change  
    Controls: 8   Collagen-induced PLT activation No significant change  
        Arachidonic acid-induced PLT activation No significant change  
        Aspirin responsiveness No significant change  
Randomized controlled trial Women 20 All: 8 weeks ADP-induced platelet aggregation ↓ ADP-induced PLT aggregation (Cases vs. Controls) trend p = 0.06 [241][123]
    Cases: 10 Cases: Endurance training, 3 non-consecutive days/week miRNA-223 expression ↑ miRNA 223 expression (Cases vs. Controls) trend p = 0.06  
    Controls: 10 Controls: no exercise training      
Randomized crossover study Women 15 All: 2 resistance exercises P-Selectin expression No significant change [250][132]
    Cases: training with blood-flow restriction (BFR)   GPIIb/IIIa activation

CD42 expression		 No significant change

No significant change		  
    Controls: training w/o BFR   CD61 expression ↓ CD61 expression (Controls post vs. pre)  
        PLT count ↑ PLT count (Cases vs. Controls)  
        Plateletcrit (PCT) ↑ PCT (Controls vs. Cases)  
        PDW No significant change  
        MPV No significant change  

References

  1. Heinonen, I.; Kalliokoski, K.K.; Hannukainen, J.C.; Duncker, D.J.; Nuutila, P.; Knuuti, J. Organ-specific physiological responses to acute physical exercise and long-term training in humans. Physiology 2014, 29, 421–436.
  2. Pedersen, B.K.; Saltin, B. Exercise as medicine-evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand. J. Med. Sci. Sports 2015, 25 (Suppl. S3), 1–72.
  3. Sharma, S.; Pelliccia, A.; Gati, S. The “Ten Commandments” for the 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease. Eur. Heart J. 2021, 42, 6–7.
  4. Dibben, G.; Faulkner, J.; Oldridge, N.; Rees, K.; Thompson, D.R.; Zwisler, A.-D.; Taylor, R.S. Exercise-based cardiac rehabilitation for coronary heart disease. Cochrane Database Syst. Rev. 2021, 11, CD001800.
  5. Alves, A.J.; Wu, Y.; Lopes, S.; Ribeiro, F.; Pescatello, L.S. Exercise to Treat Hypertension: Late Breaking News on Exercise Prescriptions That FITT. Curr. Sports Med. Rep. 2022, 21, 280–288.
  6. Doewes, R.I.; Gharibian, G.; Zadeh, F.A.; Zaman, B.A.; Vahdat, S.; Akhavan-Sigari, R. An Updated Systematic Review on the Effects of Aerobic Exercise on Human Blood Lipid Profile. Curr. Probl. Cardiol. 2023, 48, 101108.
  7. Barale, C.; Russo, I. Influence of Cardiometabolic Risk Factors on Platelet Function. Int. J. Mol. Sci. 2020, 21, 623.
  8. Scheen, A.J. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circ. Res. 2018, 122, 1439–1459.
  9. Barale, C.; Bonomo, K.; Frascaroli, C.; Morotti, A.; Guerrasio, A.; Cavalot, F.; Russo, I. Platelet function and activation markers in primary hypercholesterolemia treated with anti-PCSK9 monoclonal antibody: A 12-month follow-up. Nutr. Metab. Cardiovasc. Dis. 2020, 30, 282–291.
  10. Barale, C.; Frascaroli, C.; Senkeev, R.; Cavalot, F.; Russo, I. Simvastatin Effects on Inflammation and Platelet Activation Markers in Hypercholesterolemia. Biomed. Res. Int. 2018, 2018, 6508709.
  11. Russo, I.; Traversa, M.; Bonomo, K.; De Salve, A.; Mattiello, L.; Del Mese, P.; Doronzo, G.; Cavalot, F.; Trovati, M.; Anfossi, G. In central obesity, weight loss restores platelet sensitivity to nitric oxide and prostacyclin. Obesity 2010, 18, 788–797.
  12. Barale, C.; Cavalot, F.; Frascaroli, C.; Bonomo, K.; Morotti, A.; Guerrasio, A.; Russo, I. Association between High On-Aspirin Platelet Reactivity and Reduced Superoxide Dismutase Activity in Patients Affected by Type 2 Diabetes Mellitus or Primary Hypercholesterolemia. Int. J. Mol. Sci. 2020, 21, 4983.
  13. Förstermann, U. Nitric oxide and oxidative stress in vascular disease. Pflugers Arch. 2010, 459, 923–939.
  14. Ikarugi, H.; Shibata, M.; Shibata, S.; Ishii, H.; Taka, T.; Yamamoto, J. High intensity exercise enhances platelet reactivity to shear stress and coagulation during and after exercise. Pathophysiol. Haemost. Thromb. 2003, 33, 127–133.
  15. Sharma, S.; Merghani, A.; Mont, L. Exercise and the heart: The good, the bad, and the ugly. Eur. Heart J. 2015, 36, 1445–1453.
  16. Després, J.P. Intra-abdominal obesity: An untreated risk factor for Type 2 diabetes and cardiovascular disease. J. Endocrinol. Investig. 2006, 29, 77–82.
  17. Davì, G.; Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med. 2007, 357, 2482–2494.
  18. Davì, G.; Guagnano, M.T.; Ciabattoni, G.; Basili, S.; Falco, A.; Marinopiccoli, M.; Nutini, M.; Sensi, S.; Patrono, C. Platelet activation in obese women: Role of inflammation and oxidant stress. JAMA 2002, 288, 2008–2014.
  19. Bird, S.R.; Hawley, J.A. Update on the effects of physical activity on insulin sensitivity in humans. BMJ Open Sport. Exerc. Med. 2016, 2, e000143.
  20. Nystoriak, M.A.; Bhatnagar, A. Cardiovascular Effects and Benefits of Exercise. Front. Cardiovasc. Med. 2018, 5, 135.
  21. Black, S.E.; Mitchell, E.; Freedson, P.S.; Chipkin, S.R.; Braun, B. Improved insulin action following short-term exercise training: Role of energy and carbohydrate balance. J. Appl. Physiol. 2005, 99, 2285–2293.
  22. Newsom, S.A.; Everett, A.C.; Hinko, A.; Horowitz, J.F. A single session of low-intensity exercise is sufficient to enhance insulin sensitivity into the next day in obese adults. Diabetes Care 2013, 36, 2516–2522.
  23. Heiston, E.M.; Liu, Z.; Ballantyne, A.; Kranz, S.; Malin, S.K. A single bout of exercise improves vascular insulin sensitivity in adults with obesity. Obesity 2021, 29, 1487–1496.
  24. Falcon, C.; Pfliegler, G.; Deckmyn, H.; Vermylen, J. The platelet insulin receptor: Detection, partial characterization, and search for a function. Biochem. Biophys. Res. Commun. 1988, 157, 1190–1196.
  25. López-Aparicio, P.; Rascón, A.; Manganiello, V.C.; Andersson, K.E.; Belfrage, P.; Degerman, E. Insulin induced phosphorylation and activation of the cGMP-inhibited cAMP phosphodiesterase in human platelets. Biochem. Biophys. Res. Commun. 1992, 186, 517–523.
  26. Anfossi, G.; Russo, I.; Trovati, M. Platelet resistance to the anti-aggregating agents in the insulin resistant states. Curr. Diabetes Rev. 2006, 2, 409–430.
  27. Ferreira, I.A.; Mocking, A.I.M.; Feijge, M.A.H.; Gorter, G.; van Haeften, T.W.; Heemskerk, J.W.M.; Akkerman, J.-W.N. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 2006, 26, 417–422.
  28. Mendis, S. The contribution of the Framingham Heart Study to the prevention of cardiovascular disease: A global perspective. Prog. Cardiovasc. Dis. 2010, 53, 10–14.
  29. Lakka, H.-M.; Laaksonen, D.E.; Lakka, T.A.; Niskanen, L.K.; Kumpusalo, E.; Tuomilehto, J.; Salonen, J.T. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002, 288, 2709–2716.
  30. Mente, A.; Yusuf, S.; Islam, S.; McQueen, M.J.; Tanomsup, S.; Onen, C.L.; Rangarajan, S.; Gerstein, H.C.; Anand, S.S. INTERHEART Investigators Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. J. Am. Coll. Cardiol. 2010, 55, 2390–2398.
  31. Novo, S.; Peritore, A.; Guarneri, F.P.; Corrado, E.; Macaione, F.; Evola, S.; Novo, G. Metabolic syndrome (MetS) predicts cardio and cerebrovascular events in a twenty years follow-up. A prospective study. Atherosclerosis 2012, 223, 468–472.
  32. Towfighi, A.; Ovbiagele, B. Metabolic syndrome and stroke. Curr. Diab Rep. 2008, 8, 37–41.
  33. Van Gaal, L.F.; Mertens, I.L.; De Block, C.E. Mechanisms linking obesity with cardiovascular disease. Nature 2006, 444, 875–880.
  34. Després, J.-P.; Lemieux, I. Abdominal obesity and metabolic syndrome. Nature 2006, 444, 881–887.
  35. Kakafika, A.I.; Liberopoulos, E.N.; Karagiannis, A.; Athyros, V.G.; Mikhailidis, D.P. Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr. Vasc. Pharmacol. 2006, 4, 175–183.
  36. Ritchie, S.A.; Connell, J.M.C. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr. Metab. Cardiovasc. Dis. 2007, 17, 319–326.
  37. Mertens, I.; Van Gaal, L.F. Obesity, haemostasis and the fibrinolytic system. Obes. Rev. 2002, 3, 85–101.
  38. Anfossi, G.; Russo, I.; Trovati, M. Platelet dysfunction in central obesity. Nutr. Metab. Cardiovasc. Dis. 2009, 19, 440–449.
  39. Pignatelli, P.; Menichelli, D.; Pastori, D.; Violi, F. Oxidative stress and cardiovascular disease: New insights. Kardiol. Pol. 2018, 76, 713–722.
  40. Matsuda, M.; Shimomura, I. Increased oxidative stress in obesity: Implications for metabolic syndrome, diabetes, hypertension, dyslipidemia, atherosclerosis, and cancer. Obes. Res. Clin. Pract. 2013, 7, e330–e341.
  41. Ford, E.S.; Mokdad, A.H.; Giles, W.H.; Brown, D.W. The metabolic syndrome and antioxidant concentrations: Findings from the Third National Health and Nutrition Examination Survey. Diabetes 2003, 52, 2346–2352.
  42. Patti, M.-E.; Corvera, S. The role of mitochondria in the pathogenesis of type 2 diabetes. Endocr. Rev. 2010, 31, 364–395.
  43. Fetterman, J.L.; Holbrook, M.; Westbrook, D.G.; Brown, J.A.; Feeley, K.P.; Bretón-Romero, R.; Linder, E.A.; Berk, B.D.; Weisbrod, R.M.; Widlansky, M.E.; et al. Mitochondrial DNA damage and vascular function in patients with diabetes mellitus and atherosclerotic cardiovascular disease. Cardiovasc. Diabetol. 2016, 15, 53.
  44. Yetkin, E. Mean platelet volume not so far from being a routine diagnostic and prognostic measurement. Thromb. Haemost. 2008, 100, 3–4.
  45. Coban, E.; Ozdogan, M.; Yazicioglu, G.; Akcit, F. The mean platelet volume in patients with obesity. Int. J. Clin. Pract. 2005, 59, 981–982.
  46. Pinto, R.V.L.; Rodrigues, G.; Simões, R.L.; Porto, L.C. Analysis of Post-Sample Collection EDTA Effects on Mean Platelet Volume Values in Relation to Overweight and Obese Patient Status. Acta Haematol. 2019, 142, 149–153.
  47. Montilla, M.; Santi, M.J.; Carrozas, M.A.; Ruiz, F.A. Biomarkers of the prothrombotic state in abdominal obesity. Nutr. Hosp. 2014, 31, 1059–1066.
  48. Raoux, L.; Moszkowicz, D.; Vychnevskaia, K.; Poghosyan, T.; Beauchet, A.; Clauser, S.; Bretault, M.; Czernichow, S.; Carette, C.; Bouillot, J.-L. Effect of Bariatric Surgery-Induced Weight Loss on Platelet Count and Mean Platelet Volume: A 12-Month Follow-Up Study. Obes. Surg. 2017, 27, 387–393.
  49. Bielinski, S.J.; Berardi, C.; Decker, P.A.; Kirsch, P.S.; Larson, N.B.; Pankow, J.S.; Sale, M.; de Andrade, M.; Sicotte, H.; Tang, W.; et al. P-selectin and subclinical and clinical atherosclerosis: The Multi-Ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2015, 240, 3–9.
  50. De Pergola, G.; Pannacciulli, N.; Coviello, M.; Scarangella, A.; Di Roma, P.; Caringella, M.; Venneri, M.T.; Quaranta, M.; Giorgino, R. sP-selectin plasma levels in obesity: Association with insulin resistance and related metabolic and prothrombotic factors. Nutr. Metab. Cardiovasc. Dis. 2008, 18, 227–232.
  51. Audoly, L.P.; Rocca, B.; Fabre, J.E.; Koller, B.H.; Thomas, D.; Loeb, A.L.; Coffman, T.M.; FitzGerald, G.A. Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo. Circulation 2000, 101, 2833–2840.
  52. Horng, T.; Hotamisligil, G.S. Linking the inflammasome to obesity-related disease. Nat. Med. 2011, 17, 164–165.
  53. Murakami, T.; Horigome, H.; Tanaka, K.; Nakata, Y.; Ohkawara, K.; Katayama, Y.; Matsui, A. Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb. Res. 2007, 119, 45–53.
  54. Grande, R.; Dovizio, M.; Marcone, S.; Szklanna, P.B.; Bruno, A.; Ebhardt, H.A.; Cassidy, H.; Ní Áinle, F.; Caprodossi, A.; Lanuti, P.; et al. Platelet-Derived Microparticles From Obese Individuals: Characterization of Number, Size, Proteomics, and Crosstalk With Cancer and Endothelial Cells. Front. Pharmacol. 2019, 10, 7.
  55. Russo, I.; Del Mese, P.; Doronzo, G.; De Salve, A.; Secchi, M.; Trovati, M.; Anfossi, G. Platelet resistance to the antiaggregatory cyclic nucleotides in central obesity involves reduced phosphorylation of vasodilator-stimulated phosphoprotein. Clin. Chem. 2007, 53, 1053–1060.
  56. Anfossi, G.; Russo, I.; Massucco, P.; Mattiello, L.; Doronzo, G.; De Salve, A.; Trovati, M. Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: Possible role in platelet hyperactivation in obesity. Eur. J. Clin. Investig. 2004, 34, 482–489.
  57. Russo, I.; Viretto, M.; Barale, C.; Mattiello, L.; Doronzo, G.; Pagliarino, A.; Cavalot, F.; Trovati, M.; Anfossi, G. High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets. Diabetes 2012, 61, 2913–2921.
  58. Kawahara, Y.; Yamanishi, J.; Fukuzaki, H. Inhibitory action of guanosine 3′,5′-monophosphate on thrombin-induced calcium mobilization in human platelets. Thromb. Res. 1984, 33, 203–209.
  59. Resnick, L.M. Cellular ions in hypertension, insulin resistance, obesity, and diabetes: A unifying theme. J. Am. Soc. Nephrol. 1992, 3, S78–S85.
  60. Anfossi, G.; Mularoni, E.M.; Burzacca, S.; Ponziani, M.C.; Massucco, P.; Mattiello, L.; Cavalot, F.; Trovati, M. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 1998, 21, 121–126.
  61. Hou, L.; Wang, Q.; Pan, B.; Li, R.; Li, Y.; He, J.; Qin, T.; Cao, L.; Zhang, N.; Cao, C.; et al. Exercise modalities for type 2 diabetes: A systematic review and network meta-analysis of randomized trials. Diabetes Metab. Res. Rev. 2023, 39, e3591.
  62. Khalafi, M.; Symonds, M.E.; Ghasemi, F.; Rosenkranz, S.K.; Rohani, H.; Sakhaei, M.H. The effects of exercise training on postprandial glycemia and insulinemia in adults with overweight or obesity and with cardiometabolic disorders: A systematic review and meta-analysis. Diabetes Res. Clin. Pract. 2023, 201, 110741.
  63. Rauramaa, R.; Salonen, J.T.; Seppänen, K.; Salonen, R.; Venäläinen, J.M.; Ihanainen, M.; Rissanen, V. Inhibition of platelet aggregability by moderate-intensity physical exercise: A randomized clinical trial in overweight men. Circulation 1986, 74, 939–944.
  64. Keating, F.K.; Schneider, D.J.; Savage, P.D.; Bunn, J.Y.; Harvey-Berino, J.; Ludlow, M.; Toth, M.J.; Ades, P.A. Effect of exercise training and weight loss on platelet reactivity in overweight patients with coronary artery disease. J. Cardiopulm. Rehabil. Prev. 2013, 33, 371–377.
  65. Lamprecht, M.; Moussalli, H.; Ledinski, G.; Leschnik, B.; Schlagenhauf, A.; Koestenberger, M.; Polt, G.; Cvirn, G. Effects of a single bout of walking exercise on blood coagulation parameters in obese women. J. Appl. Physiol. 2013, 115, 57–63.
  66. Skouras, A.Z.; Antonakis-Karamintzas, D.; Tsantes, A.G.; Triantafyllou, A.; Papagiannis, G.; Tsolakis, C.; Koulouvaris, P. The Acute and Chronic Effects of Resistance and Aerobic Exercise in Hemostatic Balance: A Brief Review. Sports 2023, 11, 74.
  67. Rigamonti, A.E.; Bollati, V.; Pergoli, L.; Iodice, S.; De Col, A.; Tamini, S.; Cicolini, S.; Tringali, G.; De Micheli, R.; Cella, S.G.; et al. Effects of an acute bout of exercise on circulating extracellular vesicles: Tissue-, sex-, and BMI-related differences. Int. J. Obes. 2020, 44, 1108–1118.
  68. Dallak, M.; Bin-Jaliah, I.; Sakr, H.F.; Al-Ani, B.; Haidara, M.A. Swim exercise inhibits hemostatic abnormalities in a rat model of obesity and insulin resistance. Arch. Physiol. Biochem. 2019, 125, 79–84.
  69. Wen, J.; Huang, Y.; Lu, Y.; Yuan, H. Associations of non-high-density lipoprotein cholesterol, triglycerides and the total cholesterol/HDL-c ratio with arterial stiffness independent of low-density lipoprotein cholesterol in a Chinese population. Hypertens. Res. 2019, 42, 1223–1230.
  70. Lacoste, L.; Lam, J.Y.; Hung, J.; Letchacovski, G.; Solymoss, C.B.; Waters, D. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995, 92, 3172–3177.
  71. Morotti, A.; Barale, C.; Melchionda, E.; Russo, I. Platelet Redox Imbalance in Hypercholesterolemia: A Big Problem for a Small Cell. Int. J. Mol. Sci. 2022, 23, 11446.
  72. Davì, G.; Romano, M.; Mezzetti, A.; Procopio, A.; Iacobelli, S.; Antidormi, T.; Bucciarelli, T.; Alessandrini, P.; Cuccurullo, F.; Bittolo Bon, G. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation 1998, 97, 953–957.
  73. Magwenzi, S.; Woodward, C.; Wraith, K.S.; Aburima, A.; Raslan, Z.; Jones, H.; McNeil, C.; Wheatcroft, S.; Yuldasheva, N.; Febbriao, M.; et al. Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade. Blood 2015, 125, 2693–2703.
  74. Carnevale, R.; Bartimoccia, S.; Nocella, C.; Di Santo, S.; Loffredo, L.; Illuminati, G.; Lombardi, E.; Boz, V.; Del Ben, M.; De Marco, L.; et al. LDL oxidation by platelets propagates platelet activation via an oxidative stress-mediated mechanism. Atherosclerosis 2014, 237, 108–116.
  75. Podrez, E.A.; Byzova, T.V.; Febbraio, M.; Salomon, R.G.; Ma, Y.; Valiyaveettil, M.; Poliakov, E.; Sun, M.; Finton, P.J.; Curtis, B.R.; et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat. Med. 2007, 13, 1086–1095.
  76. Betteridge, D.J.; Cooper, M.B.; Saggerson, E.D.; Prichard, B.N.; Tan, K.C.; Ling, E.; Barbera, G.; McCarthy, S.; Smith, C.C. Platelet function in patients with hypercholesterolaemia. Eur. J. Clin. Invest. 1994, 24 (Suppl. S1), 30–33.
  77. Combescure, C.; Fontana, P.; Mallouk, N.; Berdague, P.; Labruyere, C.; Barazer, I.; Gris, J.C.; Laporte, S.; Fabbro-Peray, P.; Reny, J.L.; et al. Clinical implications of clopidogrel non-response in cardiovascular patients: A systematic review and meta-analysis. J. Thromb. Haemost. 2010, 8, 923–933.
  78. Sofi, F.; Marcucci, R.; Gori, A.M.; Giusti, B.; Abbate, R.; Gensini, G.F. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis. Thromb. Haemost. 2010, 103, 841–848.
  79. Stone, G.W.; Witzenbichler, B.; Weisz, G.; Rinaldi, M.J.; Neumann, F.-J.; Metzger, D.C.; Henry, T.D.; Cox, D.A.; Duffy, P.L.; Mazzaferri, E.; et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): A prospective multicentre registry study. Lancet 2013, 382, 614–623.
  80. Valiyaveettil, M.; Podrez, E.A. Platelet hyperreactivity, scavenger receptors and atherothrombosis. J. Thromb. Haemost. 2009, 7 (Suppl. S1), 218–221.
  81. Ma, Y.; Ashraf, M.Z.; Podrez, E.A. Scavenger receptor BI modulates platelet reactivity and thrombosis in dyslipidemia. Blood 2010, 116, 1932–1941.
  82. Akkerman, J.W.N. From low-density lipoprotein to platelet activation. Int. J. Biochem. Cell Biol. 2008, 40, 2374–2378.
  83. Vona, R.; Gambardella, L.; Cittadini, C.; Straface, E.; Pietraforte, D. Biomarkers of Oxidative Stress in Metabolic Syndrome and Associated Diseases. Oxid. Med. Cell Longev. 2019, 2019, 8267234.
  84. Tang, W.H.; Stitham, J.; Jin, Y.; Liu, R.; Lee, S.H.; Du, J.; Atteya, G.; Gleim, S.; Spollett, G.; Martin, K.; et al. Aldose reductase-mediated phosphorylation of p53 leads to mitochondrial dysfunction and damage in diabetic platelets. Circulation 2014, 129, 1598–1609.
  85. Pawlowska, Z.; Swiatkowska, M.; Krzeslowska, J.; Pawlicki, L.; Cierniewski, C.S. Increased platelet-fibrinogen interaction in patients with hypercholesterolemia and hypertriglyceridemia. Atherosclerosis 1993, 103, 13–20.
  86. Relou, I.A.M.; Hackeng, C.M.; Akkerman, J.-W.N.; Malle, E. Low-density lipoprotein and its effect on human blood platelets. Cell Mol. Life Sci. 2003, 60, 961–971.
  87. Naseem, K.M. The role of nitric oxide in cardiovascular diseases. Mol. Aspects Med. 2005, 26, 33–65.
  88. Barale, C.; Frascaroli, C.; Cavalot, F.; Russo, I. Hypercholesterolemia impairs the Glucagon-like peptide 1 action on platelets: Effects of a lipid-lowering treatment with simvastatin. Thromb. Res. 2019, 180, 74–85.
  89. Willoughby, S.R.; Stewart, S.; Holmes, A.S.; Chirkov, Y.Y.; Horowitz, J.D. Platelet nitric oxide responsiveness: A novel prognostic marker in acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol. 2005, 25, 2661–2666.
  90. Riba, R.; Nicolaou, A.; Troxler, M.; Homer-Vaniasinkam, S.; Naseem, K.M. Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels. Atherosclerosis 2004, 175, 69–75.
  91. Barale, C.; Buracco, S.; Cavalot, F.; Frascaroli, C.; Guerrasio, A.; Russo, I. Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation. Thromb. Haemost. 2017, 117, 1115–1128.
  92. Alber, H.F.; Frick, M.; Suessenbacher, A.; Doerler, J.; Schirmer, M.; Stocker, E.-M.; Dichtl, W.; Pachinger, O.; Weidinger, F. Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study. Am. Heart J. 2006, 151, 139.
  93. Pignatelli, P.; Carnevale, R.; Cangemi, R.; Loffredo, L.; Sanguigni, V.; Stefanutti, C.; Basili, S.; Violi, F. Atorvastatin inhibits gp91phox circulating levels in patients with hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 2010, 30, 360–367.
  94. Bea, F.; Blessing, E.; Shelley, M.I.; Shultz, J.M.; Rosenfeld, M.E. Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: Potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis 2003, 167, 187–194.
  95. Tannous, M.; Cheung, R.; Vignini, A.; Mutus, B. Atorvastatin increases ecNOS levels in human platelets of hyperlipidemic subjects. Thromb. Haemost. 1999, 82, 1390–1394.
  96. Pignatelli, P.; Sanguigni, V.; Lenti, L.; Loffredo, L.; Carnevale, R.; Sorge, R.; Violi, F. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: Effect of atorvastatin. J. Thromb. Haemost. 2007, 5, 1170–1178.
  97. Cammisotto, V.; Baratta, F.; Castellani, V.; Bartimoccia, S.; Nocella, C.; D’Erasmo, L.; Cocomello, N.; Barale, C.; Scicali, R.; Di Pino, A.; et al. Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. Int. J. Mol. Sci. 2021, 22, 7193.
  98. Pedersen, B.K.; Saltin, B. Evidence for prescribing exercise as therapy in chronic disease. Scand. J. Med. Sci. Sports 2006, 16 (Suppl. S1), 3–63.
  99. Aadahl, M.; Kjaer, M.; Jørgensen, T. Associations between overall physical activity level and cardiovascular risk factors in an adult population. Eur. J. Epidemiol. 2007, 22, 369–378.
  100. Mann, S.; Beedie, C.; Jimenez, A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: Review, synthesis and recommendations. Sports Med. 2014, 44, 211–221.
  101. Alvarez-Jimenez, L.; Moreno-Cabañas, A.; Ramirez-Jimenez, M.; Morales-Palomo, F.; Ortega, J.F.; Mora-Rodriguez, R. Effectiveness of statins vs. exercise on reducing postprandial hypertriglyceridemia in dyslipidemic population: A systematic review and network meta-analysis. J. Sport. Health Sci. 2022, 11, 567–577.
  102. Pearson, R.C.; Cogan, B.; Garcia, S.A.; Jenkins, N.T. Effect of Prior Exercise on Postprandial Lipemia: An Updated Meta-Analysis and Systematic Review. Int. J. Sport. Nutr. Exerc. Metab. 2022, 32, 501–518.
  103. Katzman, P.L.; Bose, R.; Henry, S.; McLean, D.L.; Walker, S.; Fyfe, C.; Perry, Y.; Mymin, D.; Bolli, P. Serum lipid profile determines platelet reactivity to native and modified LDL-cholesterol in humans. Thromb. Haemost. 1994, 71, 627–632.
  104. Weidtmann, A.; Scheithe, R.; Hrboticky, N.; Pietsch, A.; Lorenz, R.; Siess, W. Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2. Arterioscler. Thromb. Vasc. Biol. 1995, 15, 1131–1138.
  105. Hsu, H.C.; Lee, Y.T.; Chen, M.F. Exercise shifts the platelet aggregation modulatory role from native to mildly oxidized low-density lipoprotein. Med. Sci. Sports Exerc. 2000, 32, 933–939.
  106. Wang, J.-S.; Chow, S.-E. Effects of exercise training and detraining on oxidized low-density lipoprotein-potentiated platelet function in men. Arch. Phys. Med. Rehabil. 2004, 85, 1531–1537.
  107. Su, X.; Yu, X.; Chen, R.; Bian, W. Swimming improves platelet dysfunction in mice fed with a high-fat diet. Arch. Physiol. Biochem. 2023, 129, 198–203.
  108. Vazzana, N.; Ganci, A.; Cefalù, A.B.; Lattanzio, S.; Noto, D.; Santoro, N.; Saggini, R.; Puccetti, L.; Averna, M.; Davì, G. Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype. J. Am. Heart Assoc. 2013, 2, e000063.
  109. Sonmez, O.; Sonmez, M. Role of platelets in immune system and inflammation. Porto Biomed. J. 2017, 2, 311–314.
  110. Carr, M.E. Diabetes mellitus: A hypercoagulable state. J. Diabetes Complicat. 2001, 15, 44–54.
  111. Kaur, R.; Kaur, M.; Singh, J. Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: Molecular insights and therapeutic strategies. Cardiovasc. Diabetol. 2018, 17, 121.
  112. Ghoshal, K.; Bhattacharyya, M. Overview of platelet physiology: Its hemostatic and nonhemostatic role in disease pathogenesis. Sci. World J. 2014, 2014, 781857.
  113. Bosco, O.; Vizio, B.; Gruden, G.; Schiavello, M.; Lorenzati, B.; Cavallo-Perin, P.; Russo, I.; Montrucchio, G.; Lupia, E. Thrombopoietin Contributes to Enhanced Platelet Activation in Patients with Type 1 Diabetes Mellitus. Int. J. Mol. Sci. 2021, 22, 7032.
  114. Ferreiro, J.L.; Gómez-Hospital, J.A.; Angiolillo, D.J. Platelet abnormalities in diabetes mellitus. Diabetes Vasc. Dis. Res. 2010, 7, 251–259.
  115. Santilli, F.; Simeone, P.G.; Guagnano, M.T.; Leo, M.; Maccarone, M.T.; Di Castelnuovo, A.; Sborgia, C.; Bonadonna, R.C.; Angelucci, E.; Federico, V.; et al. Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes. Diabetes Care 2017, 40, 1556–1564.
  116. Santilli, F.; Formoso, G.; Sbraccia, P.; Averna, M.; Miccoli, R.; Di Fulvio, P.; Ganci, A.; Pulizzi, N.; Lattanzio, S.; Ciabattoni, G.; et al. Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J. Thromb. Haemost. 2010, 8, 828–837.
  117. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352, 837–853.
  118. Holman, R.R.; Paul, S.K.; Bethel, M.A.; Matthews, D.R.; Neil, H.A.W. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J. Med. 2008, 359, 1577–1589.
  119. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein, H.C.; Miller, M.E.; Byington, R.P.; Goff, D.C.; Bigger, J.T.; Buse, J.B.; Cushman, W.C.; Genuth, S.; Ismail-Beigi, F.; et al. Effects of intensive glucose lowering in type 2 diabetes. N. Engl. J. Med. 2008, 358, 2545–2559.
  120. ADVANCE Collaborative Group; Patel, A.; MacMahon, S.; Chalmers, J.; Neal, B.; Billot, L.; Woodward, M.; Marre, M.; Cooper, M.; Glasziou, P.; et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008, 358, 2560–2572.
  121. Duckworth, W.; Abraira, C.; Moritz, T.; Reda, D.; Emanuele, N.; Reaven, P.D.; Zieve, F.J.; Marks, J.; Davis, S.N.; Hayward, R.; et al. Glucose control and vascular complications in veterans with type 2 diabetes. N. Engl. J. Med. 2009, 360, 129–139.
  122. Marso, S.P.; Daniels, G.H.; Brown-Frandsen, K.; Kristensen, P.; Mann, J.F.E.; Nauck, M.A.; Nissen, S.E.; Pocock, S.; Poulter, N.R.; Ravn, L.S.; et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 2016, 375, 311–322.
  123. Marso, S.P.; Bain, S.C.; Consoli, A.; Eliaschewitz, F.G.; Jódar, E.; Leiter, L.A.; Lingvay, I.; Rosenstock, J.; Seufert, J.; Warren, M.L.; et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N. Engl. J. Med. 2016, 375, 1834–1844.
  124. Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med. 2015, 373, 2117–2128.
  125. Abdul-Ghani, M.; DeFronzo, R.A.; Del Prato, S.; Chilton, R.; Singh, R.; Ryder, R.E.J. Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived? Diabetes Care 2017, 40, 813–820.
  126. Way, K.L.; Hackett, D.A.; Baker, M.K.; Johnson, N.A. The Effect of Regular Exercise on Insulin Sensitivity in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Metab. J. 2016, 40, 253–271.
  127. Marwick, T.H.; Hordern, M.D.; Miller, T.; Chyun, D.A.; Bertoni, A.G.; Blumenthal, R.S.; Philippides, G.; Rocchini, A.; Council on Clinical Cardiology, American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee; Council on Cardiovascular Disease in the Young; et al. Exercise training for type 2 diabetes mellitus: Impact on cardiovascular risk: A scientific statement from the American Heart Association. Circulation 2009, 119, 3244–3262.
  128. Akbarinia, A.; Kargarfard, M.; Naderi, M. Aerobic training improves platelet function in type 2 diabetic patients: Role of microRNA-130a and GPIIb. Acta Diabetol. 2018, 55, 893–899.
  129. Taghizadeh, M.; Kargarfard, M.; Braune, S.; Jung, F.; Naderi, M. Long-term aerobic exercise training in type two diabetic patients alters the expression of miRNA-223 and its corresponding target, the P2RY12 receptor, attenuating platelet function. Clin. Hemorheol. Microcirc. 2022, 80, 107–116.
  130. Taghizadeh, M.; Ahmadizad, S.; Naderi, M. Effects of endurance training on hsa-miR-223, P2RY12 receptor expression and platelet function in type 2 diabetic patients. Clin. Hemorheol. Microcirc. 2018, 68, 391–399.
  131. Bratseth, V.; Chiva-Blanch, G.; Byrkjeland, R.; Solheim, S.; Arnesen, H.; Seljeflot, I. Elevated levels of circulating microvesicles in coronary artery disease patients with type 2 diabetes and albuminuria: Effects of exercise training. Diabetes Vasc. Dis. Res. 2019, 16, 431–439.
  132. Çakır, H.; Kaymaz, C.; Tanboga, İ.H.; Çakır, H.; Tokgöz, H.C.; Hakgör, A.; Akbal, Ö.Y.; Er, F.; Topal, D.; Mutluer, F.O.; et al. Increased exercise-related platelet activation assessed by impedance aggregometry in diabetic patients despite aspirin therapy. J. Thromb. Thrombolysis 2019, 47, 396–402.
  133. Whyte, J.J.; Laughlin, M.H. The effects of acute and chronic exercise on the vasculature. Acta Physiol. 2010, 199, 441–450.
  134. Francois, M.E.; Myette-Cote, E.; Bammert, T.D.; Durrer, C.; Neudorf, H.; DeSouza, C.A.; Little, J.P. Carbohydrate restriction with postmeal walking effectively mitigates postprandial hyperglycemia and improves endothelial function in type 2 diabetes. Am. J. Physiol. Heart Circ. Physiol. 2018, 314, H105–H113.
  135. Ceriello, A.; Esposito, K.; Piconi, L.; Ihnat, M.A.; Thorpe, J.E.; Testa, R.; Boemi, M.; Giugliano, D. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes 2008, 57, 1349–1354.
  136. Creager, M.A.; Lüscher, T.F.; Cosentino, F.; Beckman, J.A. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003, 108, 1527–1532.
  137. Ceriello, A.; Kumar, S.; Piconi, L.; Esposito, K.; Giugliano, D. Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 2007, 30, 649–654.
  138. Scheinowitz, M.; Pakala, R.; Ben-Dor, I.; Lemesle, G.; Torguson, R.; Pichard, A.D.; Lindsay, J.; Waksman, R. Platelet reactivity in diabetic patients subjected to acute exercise stress test. Cardiovasc. Revasc. Med. 2011, 12, 20–24.
  139. Fini, E.M.; Salimian, M.; Ahmadizad, S. Responses of platelet CD markers and indices to resistance exercise with and without blood flow restriction in patients with type 2 diabetes. Clin. Hemorheol. Microcirc. 2022, 80, 281–289.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback